HSV antivirals - current and future treatment options

Area of Science:

• Virology
• Infectious Diseases
• Antiviral Drug Development

Background:

• Herpes simplex virus (HSV) causes a spectrum of infections, from mild sores to severe, life-threatening conditions.
• Current approved HSV treatments primarily consist of nucleoside analogs.
• There is a need for novel therapeutic strategies to combat HSV infections.

Purpose of the Study:

• To review the current landscape of herpes simplex virus (HSV) treatments.
• To highlight emerging antiviral approaches, including therapeutic vaccines and small molecules.
• To discuss the potential of novel helicase-primase inhibitors for HSV treatment.

Main Methods:

• Review of existing literature on HSV treatments.
• Analysis of clinical development status for novel antiviral therapies.
• Focus on small molecule inhibitors targeting the HSV helicase-primase complex.

Main Results:

• The most advanced therapeutic vaccines for HSV have completed Phase 2 clinical development.
• Several small molecule antivirals are under development for genital and labial HSV.
• Two novel helicase-primase inhibitors, amenamevir and pritelivir, show promising Phase 2 data.

Conclusions:

• Novel therapeutic vaccines and small molecules represent promising avenues for HSV treatment.
• Helicase-primase inhibitors, such as amenamevir and pritelivir, are a key area of interest with positive early clinical results.
• Continued research into these novel approaches may lead to improved management of HSV infections.